GTBP Stock Catalyst: GT Biopharma Provided Enrollment Update on Phase 1 Trial of GTB-3650

Oct 7, 2025 · 7:58pm ET

The update pertains to the treatment of relapsed or refractory CD33 expressing hematologic malignancies.

Max move

+87.6%

High of day $1.37

Sparker timei

7:58pm ET

GTBP · Oct 7, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

GT Biopharma, Inc. (GTBP) announced on October 8, 2025, an enrollment update on the Phase 1 trial of its investigational drug GTB-3650. The trial is focused on treating patients with relapsed or refractory CD33 expressing hematologic malignancies.

The company did not provide specific figures on patient enrollment or trial progress in this update.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time GTBP sparks.

Download Sniper App →

Catch the next GTBP-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →